OBJECTIVE: The objective of the study was to determine the frequency of fetal death in women 40 years of age or older (AMA). STUDY DESIGN: Retrospective study of all singleton pregnancies delivered at our institution between the years 1989 and 2004 was performed. The primary outcome measure was the risk of fetal death at various gestational ages. We also investigated the frequency of maternal comorbidities, preterm delivery (PTD), and low and very low birth weights (LBW, VLBW). RESULTS: Data were available for 126,402 singleton deliveries. AMA was an independent risk factor for fetal death at 28-31 weeks (adjusted odds ratio [AOR] 2.93, 95% confidence interval [CI] 1.76-4.92), 32-36 (AOR 1.73, 95% CI 1.05-2.83), 37-39 weeks (AOR 1.63, 95% CI 0.97-2.75), and 40-41 weeks (AOR 2.28, 95% CI 1.18-4.4). AMA was associated with increased rates of PTD, LBW, and VLBW. CONCLUSION: AMA is associated with an increased rate of fetal death and other adverse obstetrical outcomes. Antepartum fetal surveillance may be warranted in these women.
OBJECTIVE: The objective of the study was to determine the frequency of fetal death in women 40 years of age or older (AMA). STUDY DESIGN: Retrospective study of all singleton pregnancies delivered at our institution between the years 1989 and 2004 was performed. The primary outcome measure was the risk of fetal death at various gestational ages. We also investigated the frequency of maternal comorbidities, preterm delivery (PTD), and low and very low birth weights (LBW, VLBW). RESULTS: Data were available for 126,402 singleton deliveries. AMA was an independent risk factor for fetal death at 28-31 weeks (adjusted odds ratio [AOR] 2.93, 95% confidence interval [CI] 1.76-4.92), 32-36 (AOR 1.73, 95% CI 1.05-2.83), 37-39 weeks (AOR 1.63, 95% CI 0.97-2.75), and 40-41 weeks (AOR 2.28, 95% CI 1.18-4.4). AMA was associated with increased rates of PTD, LBW, and VLBW. CONCLUSION: AMA is associated with an increased rate of fetal death and other adverse obstetrical outcomes. Antepartum fetal surveillance may be warranted in these women.
Authors: Patricia A Cavazos-Rehg; Melissa J Krauss; Edward L Spitznagel; Kerry Bommarito; Tessa Madden; Margaret A Olsen; Harini Subramaniam; Jeffrey F Peipert; Laura Jean Bierut Journal: Matern Child Health J Date: 2015-06
Authors: Rani Fritz; Susan Klugman; Harry Lieman; Jay Schulkin; Laura Taouk; Neko Castleberry; Erkan Buyuk Journal: J Assist Reprod Genet Date: 2018-08-02 Impact factor: 3.412
Authors: Louise C Kenny; Tina Lavender; Roseanne McNamee; Sinéad M O'Neill; Tracey Mills; Ali S Khashan Journal: PLoS One Date: 2013-02-20 Impact factor: 3.240
Authors: S Grignolo; R Agnello; D Gerbaldo; C Gotta; C Alicino; F Del Puente; L Taramasso; B Bruzzone; C Gustavino; S Trasino; A DE Maria; G Icardi; C Viscoli; A DI Biagio Journal: Epidemiol Infect Date: 2017-03-22 Impact factor: 4.434
Authors: Chris R Cardwell; Lars C Stene; Geir Joner; Max K Bulsara; Ondrej Cinek; Joachim Rosenbauer; Johnny Ludvigsson; Mireia Jané; Jannet Svensson; Michael J Goldacre; Thomas Waldhoer; Przemyslawa Jarosz-Chobot; Suely G A Gimeno; Lee-Ming Chuang; Roger C Parslow; Emma J K Wadsworth; Amanda Chetwynd; Paolo Pozzilli; Girts Brigis; Brone Urbonaite; Sandra Sipetic; Edith Schober; Gabriele Devoti; Constantin Ionescu-Tirgoviste; Carine E de Beaufort; Denka Stoyanov; Karsten Buschard; Chris C Patterson Journal: Diabetes Date: 2009-10-29 Impact factor: 9.461
Authors: Sol Pia Juárez; Helena Honkaniemi; Amy F Heshmati; Enrico Debiasi; Andrea Dunlavy; Anders Hjern; Mikael Rostila; Eleonora Mussino; Srinivasa Vittal Katikireddi; Ann-Zofie Duvander Journal: BMJ Open Date: 2021-06-09 Impact factor: 3.006